<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/21CFR600.html">Part 600
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 600.2  Mailing addresses.
                            </h3>
                            <p class="depth1"><em>(a)</em> Licensed biological products regulated by the Center for Biologics Evaluation and Research (CBER). Unless otherwise stated in paragraphs (c) or (d) of this section, or as otherwise prescribed by FDA regulation, all submissions to CBER referenced in parts 600 through 680 of this chapter, as applicable, must be sent to: Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448. Examples of such submissions include: Biologics license applications (BLAs) and their amendments and supplements, adverse experience reports, biological product deviation reports, fatality reports, and other correspondence. Biological products samples must not be sent to this address but must be sent to the address in paragraph (c) of this section.</p><p class="depth1"><em>(b)</em> Licensed biological products regulated by the Center for Drug Evaluation and Research (CDER). Unless otherwise stated in paragraphs (b)(1), (b)(2), (b)(3), or (c) of this section, or as otherwise prescribed by FDA regulation, all submissions to CDER referenced in parts 600, 601, and 610 of this chapter, as applicable, must be sent to: CDER Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901B Ammendale Rd., Beltsville, MD 20705. Examples of such submissions include: BLAs and their amendments and supplements, and other correspondence.</p><p class="depth2"><em>(1)</em> Biological Product Deviation Reporting (CDER). All biological product deviation reports required under Sec. 600.14 must be sent to: Division of Compliance Risk Management and Surveillance, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002.</p><p class="depth2"><em>(2)</em> Postmarketing Adverse Experience Reporting (CDER). All postmarketing reports required under Sec. 600.80 must be sent to: Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.</p><p class="depth2"><em>(3)</em> Advertising and Promotional Labeling (CDER). All advertising and promotional labeling supplements required under Sec. 601.12(f) of this chapter must be sent to: Division of Drug Marketing, Advertising and Communication, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.</p><p class="depth1"><em>(c)</em> Samples and Protocols for licensed biological products regulated by CBER or CDER. (1) Biological product samples and/or protocols, other than radioactive biological product samples and protocols, required under Sec. Sec. 600.13, 600.22, 601.15, 610.2, 660.6, 660.36, or 660.46 of this chapter must be sent by courier service to: Sample Custodian (ATTN: HFM-672), Food and Drug Administration, Center for Biologics Evaluation and Research, Bldg: NLRC-B, rm. 113, 5516 Nicholson Lane, Kensington, MD 20895. The protocol(s) may be placed in the box used to ship the samples to CBER. A cover letter should not be included when submitting the protocol with the sample unless it contains pertinent information affecting the release of the lot.</p><p class="depth2"><em>(1)</em> Biological product samples and/or protocols, other than radioactive biological product samples and protocols, required under Sec. Sec. 600.13, 600.22, 601.15, 610.2, 660.6, 660.36, or 660.46 of this chapter must be sent by courier service to: Sample Custodian (ATTN: HFM-672), Food and Drug Administration, Center for Biologics Evaluation and Research, Bldg: NLRC-B, rm. 113, 5516 Nicholson Lane, Kensington, MD 20895. The protocol(s) may be placed in the box used to ship the samples to CBER. A cover letter should not be included when submitting the protocol with the sample unless it contains pertinent information affecting the release of the lot.</p><p class="depth2"><em>(2)</em> Radioactive biological products required under Sec. 610.2 of this chapter must be sent by courier service to: Sample Custodian (ATTN: HFM-672), Food and Drug Administration, Center for Biologics Evaluation and Research, Nicholson Lane Research Center, c/o Radiation Safety Office, National Institutes of Health, 21 Wilson Dr., rm. 107, Bethesda, MD 20892-6780.</p><p class="depth1"><em>(d)</em> Vaccine Adverse Event Reporting System (VAERS). All VAERS reports as specified in Sec. 600.80(c) must be sent to: Vaccine Adverse Event Reporting System (VAERS), P.O. Box 1100, Rockville, MD 20849-1100.</p><p class="depth1"><em>(e)</em> Address information for submissions to CBER and CDER other than those listed in parts 600 through 680 of this chapter are included directly in the applicable regulations.</p><p class="depth1"><em>(f)</em> Obtain updated mailing address information for biological products regulated by CBER at http://www.fda.gov/cber/pubinquire.htm, or for biological products regulated by CDER at http://www.fda.gov/cder/biologics/default.htm.
[70 FR 14981, Mar. 24, 2005, as amended at 74 FR 13114, Mar. 26, 2009; 78 FR 19585, Apr. 2, 2013]</p><p class="depth2">Effective Date Note: At 79 FR 33090, June 10, 2014, Sec. 600.2 was amended as follows, effective June 10, 2015.</p><p class="depth2">a. In paragraph (a) by removing the phrase ``paragraphs (c) or (d)'' and adding in its place ``paragraph (c)'', and by removing the phrase ``adverse experience reports'';</p><p class="depth2">b. In paragraph (b) introductory text by removing the phrase ``paragraphs (b)(1), (b)(2), (b)(3), or (c)'' and adding in its place ``paragraphs (b)(1), (b)(2), or (c) ``</p><p class="depth2">c. By removing paragraph (b)(2) and redesignating paragraph (b)(3) as paragraph (b)(2);</p><p class="depth2">d. By removing paragraph (d) and redesignating paragraphs (e) and (f) as paragraphs (d) and (e).</p><p class="depth2">e. In newly redesignated paragraph (e) by removing the Web address ``http://www.fda.gov/cber/pubinquire.htm'' and adding in its place ``http://www.fda.gov/BiologicsBloodVaccines/default.htm'' and by removing the Web address ``http://www.fda.gov/cder/biologics/default.htm'' and adding in its place ``http://www.fda.gov/Drugs/default.htm''.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§.
          Code available <a href="https://github.com/anthonygarvan/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5
      </div>
    </div>
  </footer>
  </body>
</html>
